354 related articles for article (PubMed ID: 24768356)
21. Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
[TBL] [Abstract][Full Text] [Related]
22. An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.
Bristow RG; Berlin A; Dal Pra A
Br J Radiol; 2014 Mar; 87(1035):20130753. PubMed ID: 24588670
[TBL] [Abstract][Full Text] [Related]
23. Genomics to personalize care of prostate cancer.
Connors LM
J Am Assoc Nurse Pract; 2020 Feb; 32(2):106-108. PubMed ID: 32015276
[TBL] [Abstract][Full Text] [Related]
24. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA; Zafarana G; Ishkanian AS; Milosevic M; Thoms J; Have CL; Malloff CA; Lam WL; Squire JA; Pintilie M; Sykes J; Ramnarine VR; Meng A; Ahmed O; Jurisica I; van der Kwast T; Bristow RG
Clin Cancer Res; 2012 Jan; 18(1):308-16. PubMed ID: 22048240
[TBL] [Abstract][Full Text] [Related]
25. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
26. The Value of Phenotypic Precision Medicine in Prostate Cancer.
Hawkey NM; Broderick A; George DJ; Sartor O; Armstrong AJ
Oncologist; 2023 Feb; 28(2):93-104. PubMed ID: 36200788
[TBL] [Abstract][Full Text] [Related]
27. Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.
Tan SH; Petrovics G; Srivastava S
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690565
[TBL] [Abstract][Full Text] [Related]
28. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
[TBL] [Abstract][Full Text] [Related]
29. GENOMICS OF PROSTATE CANCER: CLINICAL UTILITY AND CHALLENGES.
Šamija I; Fröbe A
Acta Clin Croat; 2022 Oct; 61(Suppl 3):86. PubMed ID: 36938554
[TBL] [Abstract][Full Text] [Related]
30. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
Nguyen JK; Magi-Galluzzi C
Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
[TBL] [Abstract][Full Text] [Related]
31. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
Modena A; Iacovelli R; Scarpa A; Brunelli M; Ciccarese C; Fantinel E; Bimbatti D; Massari F; Martignoni G; Tortora G
Target Oncol; 2016 Oct; 11(5):569-577. PubMed ID: 27402433
[TBL] [Abstract][Full Text] [Related]
32. Precision medicine for prostate cancer.
Galazi M; Rodriguez-Vida A; Ng T; Mason M; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1305-15. PubMed ID: 25354871
[TBL] [Abstract][Full Text] [Related]
33. Genomic approaches to outcome prediction in prostate cancer.
Febbo PG
Cancer; 2009 Jul; 115(13 Suppl):3046-57. PubMed ID: 19544546
[TBL] [Abstract][Full Text] [Related]
34. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
35. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
36. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
37. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
38. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR
Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
